After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 93% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics ...

AbbVie is strutting into 2025 like it owns the lab, thanks to a performance cocktail of smart acquisitions, clinical wins, ...

AbbVie ( NYSE: ABBV) shares snapped seven straight sessions of gains, as the stock was down 0.9% at $193.40 on Thursday. The maker of Humira arthritis therapy added over 12% in the preceding seven ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AbbVie’s stock faced a chilly reception on May 6, plunging 4.55% and ending the day at $187.15. Despite strong fundamentals ...

Richard A. Gonzalez is the founder of AbbVie Ltd. (United Kingdom) since 2013, holding the title of Chairman & Chief Executive Officer. Current jobs include Chief Executive Officer at AbbVie ...